⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KURA News
Kura Oncology, Inc.
Kura Oncology to Participate in Three Upcoming Investor Conferences
globenewswire.com
KURA
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
KURA
VIA and Kura Apply Zero Trust Technology to Safeguard Donor Funds Sent to Haiti
prnewswire.com
VIA
KURA
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
globenewswire.com
KURA
Syncromune Continues to Strengthen Executive and Clinical Leadership with Appointment of Dr. Stephen P. Dale, M.D., as Chief Medical Officer
globenewswire.com
KURA
AZN
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
KURA
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
globenewswire.com
KURA
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
prnewswire.com
GTBP
GERN
KURA
SLS
TCRX
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
globenewswire.com
KURA
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
globenewswire.com
KURA